Actively Recruiting
Modified Urine Fetuin A as a Predictor of Deterioration of Renal Function in Patients With Resistant and Non-resistant Hypertension
Led by University Hospital Ostrava · Updated on 2023-07-27
200
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying arterial hypertension, a common cause of chronic kidney disease, to find better ways to predict early kidney function decline. This study focuses on a new urine biomarker called modified human urine Fetuin A, which may identify kidney disease progression earlier than commonly used tests like creatinine and albumin/creatinine ratio. The study particularly looks at patients with hypertension, including resistant and secondary types, to evaluate this marker's usefulness. This is an observational study without any intervention, involving patients with arterial hypertension who are treated with at least one antihypertensive medication. The study observes these patients over time, collecting urine samples to measure modified Fetuin A and other biomarkers. Participants include patients with resistant and non-resistant hypertension. There is no experimental treatment or placebo. Participants will provide urine samples and undergo tests to monitor kidney function, including the glomerular filtration rate, over one year. Researchers will also analyze correlation and changes in urine biomarkers. The study tracks kidney function decline and assesses the potential of urine Fetuin A to predict kidney damage earlier. The total duration of participation is about one year with regular evaluations to monitor outcomes and health status.
CONDITIONS
Brief Title
Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 100 years
- Diagnosis of arterial hypertension
- Treated with at least one antihypertensive medication
You will not qualify if you...
- Diabetes mellitus of any type, defined as fasting glucose >7.0 mmol/l or any glycemia >11.0 mmol/l, or HbA1c >48 mmol/mol
- Decompensated arterial hypertension defined as office blood pressure >180/110 mmHg or on Ambulatory Blood Pressure Monitoring
- Patients undergoing renal replacement therapy
- Presence of rheumatoid diseases or positive autoimmune antibody screening
- Acute infection defined as C-Reactive Protein >50 mg/l
- Severe liver impairment such as cirrhosis or very elevated liver enzymes
- Terminal incurable illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 year
Participants who undergo routine care are observed to assess kidney function and urine biomarkers over time.
Trial Site Locations
Total: 1 location
1
University Hospital Ostrava, - Department of Internal Medicine and Cardiology
Ostrava, Czech Republic, Czechia, 70852
Actively Recruiting
Research Team
J
Jiří Hynčica
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here